A Study to Evaluate Bevacizumab and Chemotherapy or Tarceva in Treating Recurrent or Refractory NSCLC (Non-Small Cell Lung Cancer)

Conditions

• Neoplasm Recurrence, Local
• Non-Small-Cell Lung Carcinoma

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Avastin (bevacizumab) — DRUG
• Tarceva (erlotinib HCl) — DRUG

Study Details

This Phase II, multicenter, randomized trial is designed to make preliminary evaluations of the efficacy of combining bevacizumab with chemotherapy (docetaxel or pemetrexed) or Tarceva relative to chemotherapy (docetaxel or pemetrexed) alone in patients with previously treated advanced NSCLC.

Key Dates

First listed

Nov 2, 2004

Start date

Jul 31, 2004

Status verified

Jan 2008

Completion

Nov 30, 2006

Study Design

Enrollment

122 participants (actual)

Primary purpose

TREATMENT

Primary Outcome Measure

To evaluate the safety and preliminary efficacy of combining bevacizumab with chemotherapy or Tarceva relative to chemotherapy alone on patients with previously treated advanced non-small cell lung cancer.

Locations (48)

Find similar trials in Bakersfield, CA

Related Studies

• The Gut Microbiome and Immune Checkpoint Inhibitor Therapy in Solid Tumors
  Recruiting · VastBiome · Elizabethtown, Kentucky
• Dose Finding Study of Zanzalintinib With Pembrolizumab and Cetuximab in Head and Neck SCC
  PHASE1 · Recruiting · University of Chicago · Chicago, Illinois